The oral GLP-1 race has a new front-runner. Eli Lilly’s orforglipron — a once-daily, non-peptide, small-molecule GLP-1 receptor agonist — has outperformed oral semaglutide in a head-to-head Phase III trial, achieving significantly greater reductions in both blood sugar and body weight.
The ACHIEVE-3 trial (NCT06045221), published in The Lancet and presented at a major diabetes conference, randomized 1,698 adults with type 2 diabetes inadequately controlled on metformin across six countries. Participants received one of two doses of orforglipron (12 mg or 36 mg) or one of two doses of oral semaglutide (7 mg or 14 mg) for 52 weeks.
The results were unambiguous. At the highest doses, the 36 mg orforglipron group achieved a 2.2 percent reduction in HbA1c (vs. 1.4 percent for 14 mg semaglutide) and a 9.2 percent body weight reduction (vs. 5.3 percent for semaglutide) — a 73.6 percent greater relative weight loss.
Why orforglipron is different
Orforglipron represents a fundamental departure from existing GLP-1 drugs. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are peptide-based — large molecules that require complex synthesis, refrigeration, and careful oral dosing on an empty stomach. Orforglipron is a synthetic chemical compound small enough to be absorbed directly through the gut wall, enabling once-daily oral dosing with no food or water restrictions and no refrigeration.
This difference showed in the data. At 52 weeks, 85.4 percent of patients on 36 mg orforglipron achieved an HbA1c below 7.0 percent, compared to 66.1 percent on 14 mg semaglutide. For the more stringent target of HbA1c at or below 6.5 percent — essentially normal glucose levels — the advantage widened further: 76.8 percent vs. 50.9 percent.
The tolerability trade-off
The higher efficacy came with a higher side-effect burden. Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) occurred in approximately 59 percent of orforglipron recipients vs. 37-45 percent for semaglutide. Treatment discontinuation due to adverse events was 8.7-9.7 percent for orforglipron, roughly double the 4.5-4.9 percent for semaglutide.
The higher GI rates are attributed to the drug’s pharmacokinetic profile — orforglipron produces more prominent daily peak concentrations than the longer-acting semaglutide. An increase in pulse rate was also noted, though without an increase in tachycardia events. No hepatic safety signal was detected.
What the numbers mean
The absolute comparison is worth stating clearly. Patients on 36 mg orforglipron lost an average of 8.9 kg (19.6 lbs), or 9.2 percent of their baseline body weight. Patients on 14 mg semaglutide lost 5.0 kg (11.0 lbs), or 5.3 percent. The 3.9 kg (8.6 lbs) difference represents a clinically meaningful advantage — especially for patients with type 2 diabetes, where every kilogram of weight loss improves glycemic control, cardiovascular risk, and quality of life.
For glycemic control, the 0.8 percentage-point advantage in HbA1c reduction (2.2 percent vs. 1.4 percent) is large enough to shift many patients below the diagnostic threshold for diabetes.
The bigger picture
Orforglipron was originally discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018. The ACHIEVE-3 trial is the first Phase III head-to-head comparison of two oral GLP-1 agonists. Separate trials in the ATTAIN program are evaluating orforglipron in obese patients without diabetes.
The drug’s manufacturing simplicity — a small molecule made by standard chemical synthesis rather than complex peptide production — has implications for supply and cost that the peptide-based GLP-1 drugs have struggled with. If approved, orforglipron could ease the chronic shortages that have plagued the GLP-1 market since 2023.
FDA submission for obesity is expected in the second quarter of 2026; the type 2 diabetes submission is planned for later in the year.
Sources
1. ScienceDaily, “New weight loss pill beats oral Ozempic in major trial” (8 July 2026). https://www.sciencedaily.com/releases/2026/07/260707054111.htm
2. Rosenstock, J. et al., “Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3)”, The Lancet 407, 1147-1160 (2026). DOI: 10.1016/S0140-6736(26)00202-3
3. Eli Lilly, “ACHIEVE-3 Phase 3 Results” (press release, 2026).